FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with a RET Mutation By Ogkologos - November 6, 2024 720 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LIBRETTO-531 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Stress-Induced Immune Changes May Help Cancer Spread April 2, 2024 EMA Recommends Granting a Marketing Authorisation for Lisocabtagene Maraleucel February 4, 2022 Breast Cancer Survivor Fights Back After Instagram Bans Photos of Her... February 5, 2020 Breastfeeding Duration Could Influence Breast Cancer Risk, Study Shows September 27, 2019 Load more HOT NEWS COVID-19, Cancer, and Uncertainty: An Oncologist’s Perspective on Coping FDA Approves HPV Tests That Allow for Self-Collection in a Health... Five Questions With…Sharon. Obesity May Help Tumors Survive and Grow, Mouse Study Suggests
